Friday, July 20, 2018
 
 
Company News: Page (1) of 1 - 07/11/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Bioresorbable Scaffolds Report 2018: Global Strategic Business Overview & Outlook 2016-2024 - Rising Middle Class Population Aids Growth
  By PR Newswire

DUBLIN, July 11, 2018 /PRNewswire/ --

The "Bioresorbable Scaffolds - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024.

This report analyzes the worldwide markets for Bioresorbable Scaffolds in US$ Thousand.

The report profiles 17 companies including many key and niche players such as:



  • Abbott Laboratories (USA)
  • Amaranth Medical, Inc. (USA)
  • Arterial Remodeling Technologies SA (France)
  • BIOTRONIK SE & Co. KG (Germany)
  • Elixir Medical Corp. (USA)
  • Kyoto Medical Planning Co., Ltd. (Japan)
  • REVA Medical, Inc. (USA)

Key Topics Covered

1. INDUSTRY OVERVIEW
BioResorbable Scaffolds/Stents - A Prelude
Clinical Characteristics of Various Coronary Stents
Bioresorbable Vascular Scaffolds: Advantages and Challenges
Evolution of Coronory Stents
Global Coronory Stents Market - A Few Key Facts
Bioresorbable Stents - A Revolutionary Technology, Riddled with Controversies
Abbott Stops Sales of the Once Promising Absorb' Bioresorbable Stents due to Adverse Events
Impact of Abbott's Withdrawal of Absorb on the Bioresorbable Stent Industry
Challenges in Next-generation BVS Development
Other Available Bioresorbable Scaffolds Exhibit Potential
Approved Bioresorbable Scaffolds
Magmaris Exhibits Stability and Safety with Lack of Scaffold Thrombosis Occurrence
Fantom from REVA Medical
DESolve from Elixir Medical
ART from Arterial Remodeling Technologies
Bioresorbable Scaffolds in Pipeline
Current & Future Analysis
Developing Countries
Hot Spots for Growth

2. ABSORB III TRIALS - CHANGING THE FACE OF THE BIORESORBABLE STENTS INDUSTRY
Absorb Bioresorbable Scaffold/Stent Trials
Adverse Outcomes after Two Years of Placement
The ABSORB III Trials
Performance of Absorb in Smaller Vessels

3. GROWTH DRIVERS & MARKET TRENDS
Global Menace of Coronary Artery Disease (CAD)
A Major Growth Driver
Ageing Demographics and Longer Life Expectancy Bolsters Market Growth
Rising Middle Class Population Aids Growth
Rising Healthcare Expenditure: Opportunities in Store
Risk of CAD in Obesity Offers Prospects for Coronary Stenting
Diabetics at Higher Risk of Heart Diseases
The Hypertension-Cholesterol Link to Drive Demand
Spurt in Medical Tourism Offers Growth Opportunities
Metal Bioresorbable scaffolds Exhibit Improved Performance Compared to Polymer Stents
Metal Stents Vis-a-vis Other Stents
Alternative Therapies/Devices: Threats to Coronary Stents
Cell Transplantation - A Threat to Coronary Stents

4. PIPELINE ANALYSIS
Falcon from Abbott
Fortitude, Aptitude, and Magnitude from Amaranth
Renuvia from Boston Scientific
Ideal from Xenogenics
MeRes from Meril
Mirage from Manli Cardiology
Xinsorb from HuaAn Biotechnology
Firesorb from MicroPort
Unity from QualiMed

5. REGULATORY FRAMEWORK
The United States
Europe
Australia

6. PRODUCT OVERVIEW

7. RECENT INDUSTRY ACTIVITY
The DGCI Warns Against the Use of Absorb in 2.5 mm or Narrower Blood Vessels
Akesys and Elixir Medical Completes Successful Implantation of PRAVA for Peripheral Vascular Disease
Elixir Medical Showcases DESolve CX and AMITY at EuroPCR 2016
Micell Technologies Announces Commercialization of MiStent SES in Europe

8. CLINICAL TRIALS AND PRODUCT APPROVALS
Elixir Medical Confirms Excellent 5-Year Clinical Data for DESolve
Amaranth Medical Announces Nine-month Follow-up RENASCENT-II Study Results of the APTITUDE
Abbott's Absorb Receives Approval as the Japan's First Fully Dissolving Heart Stent
Amaranth Medical Initiates Clinical Study for MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold
Abbott's Absorb Receives Health Canada Approval
BIOTRONIK Obtains CE Mark Approval for Magmaris, the First Magnesium Bioresorbable Scaffold
Abbott's Absorb Receives FDA Approval
US FDA Approves Boston Scientific's SYNERGY BP-DES
Abbott Receives CE Mark for Absorb GT1
ART Receives CE Mark Clearance for its Pure Bioresorbable Scaffold

9. FOCUS ON SELECT GLOBAL PLAYERS
Abbott Laboratories (USA)
Amaranth Medical, Inc. (USA)
Arterial Remodeling Technologies SA (France)
BIOTRONIK SE & Co. KG (Germany)
Elixir Medical Corp. (USA)
Kyoto Medical Planning Co., Ltd. (Japan)
REVA Medical, Inc. (USA)

10. GLOBAL MARKET PERSPECTIVE
 
Total Companies Profiled: 17 (including Divisions/Subsidiaries 18)

  • The United States (6)
  • Japan (1)
  • Europe (5)
    • France (1)
    • Germany (2)
    • The United Kingdom (1)
    • Rest of Europe (1)
  • Asia-Pacific (Excluding Japan) (6)

For more information about this report visit https://www.researchandmarkets.com/research/nhrv5b/bioresorbable?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:http://www.prnewswire.com/news-releases/bioresorbable-scaffolds-report-2018-global-strategic-business-overview--outlook-2016-2024---rising-middle-class-population-aids-growth-300679452.html

SOURCE Research and Markets

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


 





[ServletException in:/common/ads/links.jsp] The absolute uri: http://java.sun.com/jstl/core cannot be resolved in either web.xml or the jar files deployed with this application'
About Digital Facility - Contact Us - Advertise With Us - Privacy Guidelines